47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 517
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
L’ISS Governance QualityScore de Amicus Therapeutics, Inc. en date du 1 juin 2024 est 4. Les scores principaux sont Audit : 2; Société : 2; Droits des actionnaires : 7; Compensation : 4.